Published in J Med Chem on November 12, 1993
Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res (2000) 10.78
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med (1999) 7.97
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol (2001) 4.73
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci U S A (1998) 3.18
A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (1994) 3.05
Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res (1984) 2.74
Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res (1975) 2.54
Total structure determination of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula. J Am Chem Soc (2001) 2.06
Birth defects among children of nurse-anesthetists. Anesthesiology (1974) 2.04
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. Cancer Res (2001) 1.80
Isolation of dolastatin 10 from the marine cyanobacterium Symploca species VP642 and total stereochemistry and biological evaluation of its analogue symplostatin 1. J Nat Prod (2001) 1.75
A survey of anesthetic health hazards among dentists. J Am Dent Assoc (1975) 1.70
In vivo and in vitro anticancer activity of the structurally novel and highly potent antibiotic CI-940 and its hydroxy analog (PD 114,721). Cancer Chemother Pharmacol (1986) 1.60
Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7. Proc Natl Acad Sci U S A (1999) 1.56
Toxicity of polybrominated biphenyls Firemaster BP-6 in rodents. Environ Res (1975) 1.53
Incidence of cancer among Michigan nurse-anesthetists. Anesthesiology (1973) 1.51
cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep (1980) 1.47
Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1. J Biol Chem (2000) 1.43
Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues. Cancer Res (1984) 1.42
Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs (1986) 1.41
Nitrous oxide concentrations in the dental operatory. J Oral Surg (1974) 1.40
Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors. Anticancer Res (1999) 1.40
Effects on substrate profile by mutational substitutions at positions 164 and 179 of the class A TEM(pUC19) beta-lactamase from Escherichia coli. J Biol Chem (1999) 1.39
Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide). Biochem Pharmacol (1985) 1.34
Rapid screening of environmental chemicals for estrogen receptor binding capacity. Environ Health Perspect (1998) 1.27
Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des (1991) 1.22
Isolation and cytotoxic evaluation of marine sponge-derived norterpene peroxides. J Nat Prod (1998) 1.21
In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res (1982) 1.18
Establishment of cross-resistance profiles for new agents. Cancer Treat Rep (1983) 1.18
Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res (1988) 1.18
Ligand-based identification of environmental estrogens. Chem Res Toxicol (1996) 1.17
A colon tumor model for anticancer agent evaluation. Cancer (1975) 1.17
Isolation, structure determination, and biological activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola cyanobacterial assemblages. J Nat Prod (1998) 1.15
Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes. Neoplasia (2001) 1.14
DNA damage as a basis for 4'-demethylepipodophyllotoxin-9-(4,6-O-ethylidene-beta-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res (1983) 1.14
Phytochemical glyceollins, isolated from soy, mediate antihormonal effects through estrogen receptor alpha and beta. J Clin Endocrinol Metab (2001) 1.12
Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias. J Med Chem (1987) 1.10
Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep (1978) 1.09
Symplostatin 1: A dolastatin 10 analogue from the marine cyanobacterium Symploca hydnoides. J Nat Prod (1998) 1.07
Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer (1977) 1.06
Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem (2001) 1.05
Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice. Invest New Drugs (1997) 1.02
Determination of the mutagenic activity to bacteriophage T4 of carcinogenic and noncarcinogenic compounds. Mol Pharmacol (1970) 1.02
Retention of anesthetic agents following occupational exposure. Anesth Analg (1973) 1.02
Methylene-gem-difluorocyclopropane analogues of nucleosides: synthesis, cyclopropene-methylenecyclopropane rearrangement, and biological activity. J Med Chem (2001) 1.01
Preclinical antitumor activity of XK469 (NSC 656889). Invest New Drugs (1999) 1.01
Effects of low concentrations of nitrous oxide on rat pregnancy. Anesthesiology (1973) 1.00
Novel farnesol and geranylgeraniol analogues: A potential new class of anticancer agents directed against protein prenylation. J Med Chem (1999) 0.99
Carcinogenicity of antitumor cis-platinum(II) coordination complexes in the mouse and rat. Cancer Res (1979) 0.99
Is the P388 murine tumor no longer adequate as a drug discovery model? Invest New Drugs (1987) 0.99
Antitumor efficacy of PD115934 (NSC 366140) against solid tumors of mice. Cancer Res (1990) 0.98
6-(hydroxyalkyl)penicillanates as probes for mechanisms of beta-lactamases. J Antibiot (Tokyo) (2000) 0.97
In vivo 31P NMR study of the metabolism of murine mammary 16/C adenocarcinoma and its response to chemotherapy, x-radiation, and hyperthermia. Proc Natl Acad Sci U S A (1983) 0.97
Retinoic acid-binding protein in normal tissues and experimental tumors. Cancer Res (1977) 0.96
A test of the carcinogenicity of enflurane, isoflurane, halothane, methoxyflurane, and nitrous oxide in mice. Anesth Analg (1979) 0.96
5-[(Aminoalkyl)amino]-substituted anthra[1,9-cd]pyrazol-6(2H)-ones as novel anticancer agents. Synthesis and biological evaluation. J Med Chem (1984) 0.96
Antitumor activity of ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyrido [3,4-b]pyrazin-7-ylcarbamate, 2-hydroxyethanesulfonate, hydrate (NSC 370147) against selected tumor systems in culture and in mice. Cancer Res (1990) 0.94
Response-specific adriamycin sensitivity markers provided by in vivo 31P nuclear magnetic resonance spectroscopy in murine mammary adenocarcinomas. Cancer Res (1987) 0.93
Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors. Cancer Res (1975) 0.93
Non-peptidic prenyltransferase inhibitors: diverse structural classes and surprising anti-cancer mechanisms. Curr Med Chem (2001) 0.92
Chronic exposure to methoxyflurane: a possible occupational hazard to anesthesiologists. Anesthesiology (1971) 0.92
Comparison of some carcinogenic, mutagenic, and biochemical properties of S-vinylhomocysteine and ethionine. Cancer Res (1982) 0.92
Lung cancer in patients < 50 years of age: the experience of an academic multidisciplinary program. Chest (1999) 0.92
Protein prenylation: from discovery to prospects for cancer treatment. Curr Opin Chem Biol (1998) 0.92
Cancer and congenital anomalies associated with anesthetics. Ann N Y Acad Sci (1976) 0.92
The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Invest (1990) 0.91
Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res (1982) 0.91
Effect of PD 128763, a new potent inhibitor of poly(ADP-ribose) polymerase, on X-ray-induced cellular recovery processes in Chinese hamster V79 cells. Radiat Res (1991) 0.91
Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice. Cancer Chemother Pharmacol (1989) 0.90
Regulation of metastasis-related gene expression by p53: a potential clinical implication. Mol Carcinog (1999) 0.90
Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem (1999) 0.89
Flavone acetic acid (NSC 347512)-induced DNA damage in Glasgow osteogenic sarcoma in vivo. Cancer Res (1988) 0.89
Anesthetics as a cause of abortion. Fertil Steril (1972) 0.89
Pharmacokinetic studies in mice of two new thioxanthenones (183577 and 232759) that showed preferential solid tumor activity. Clin Cancer Res (1997) 0.89
Phase I pharmacokinetic study of the novel antitumor agent SR233377. Clin Cancer Res (2000) 0.88
Mutagenicity, tumorigenicity, and electrophilic reactivity of the stereoisomeric platinum(II) complexes of 1,2-diaminocyclohexane. Cancer Res (1981) 0.88
Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice. Invest New Drugs (1996) 0.88
Anthrapyrazoles, a new class of intercalating agents with high-level, broad spectrum activity against murine tumors. Cancer Res (1985) 0.87
Preclinical pharmacokinetic, antitumor and toxicity studies with CI-994 (correction of CL-994) (N-acetyldinaline). Invest New Drugs (1997) 0.87
Activity of batracylin (NSC-320846) against solid tumors of mice. Invest New Drugs (1989) 0.86
Design, synthesis, and biological evaluation of analogues of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469). J Med Chem (2001) 0.86
Novel limonene phosphonate and farnesyl diphosphate analogues: design, synthesis, and evaluation as potential protein-farnesyl transferase inhibitors. Bioorg Med Chem (1999) 0.85
Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep (1982) 0.84
Biochemical pharmacology of the lipophilic antifolate, trimetrexate. Adv Enzyme Regul (1984) 0.83
Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts. Cancer Chemother Pharmacol (2000) 0.83
Pharmacology and toxicology of halogenated anesthetics. Adv Pharmacol Chemother (1979) 0.82
Human tumors as examined by in vivo 31P NMR in athymic mice. Biochem Biophys Res Commun (1982) 0.82
Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology. Cancer (1984) 0.81
Design and evaluation of combination chemotherapy trials in experimental animal tumor systems. Cancer Treat Rep (1979) 0.81
Biological and biochemical activities of the novel antitumor antibiotic PD 114,759 and related derivatives. Invest New Drugs (1986) 0.81
Strategies for the discovery of novel tyrosine kinase inhibitors with anticancer activity. Anticancer Drug Des (1994) 0.81
3-(3,5-Dimethoxyphenyl)-1,6-naphthyridine-2,7-diamines and related 2-urea derivatives are potent and selective inhibitors of the FGF receptor-1 tyrosine kinase. J Med Chem (2000) 0.81
Comparative molecular field analysis of the antitumor activity of 9H-thioxanthen-9-one derivatives against pancreatic ductal carcinoma 03. J Med Chem (1994) 0.81